Compositions and methods for targeted cytokine delivery
US-2024376169-A1 · Nov 14, 2024 · US
US10059753B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10059753-B2 |
| Application number | US-201615260017-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 8, 2016 |
| Priority date | Jul 6, 2016 |
| Publication date | Aug 28, 2018 |
| Grant date | Aug 28, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention provides a mutant chicken interleukin-1β protein as a chicken interleukin-1β antagonist, which has a substituted peptide at position 117 and/or 118 of wild-type chicken interleukin-1β peptides. The mutant chicken interleukin-1β protein is created by using point mutation in a method genetic engineering; it can significantly inhibit proliferation of avian virus, such as avian influenza virus, avian reovirus and Marek's disease virus, and avian inflammation response. Therefore, the mutant chicken interleukin-1β protein of the present invention can be used as antiviral and anti-inflammatory medication.
Opening claim text (preview).
What is claimed is: 1. A mutant chicken interieukin-1β protein that is derived from the chicken interleukin-1β comprising the amino acid sequence of SEQ ID NO:1, wherein the mutant comprises an amino acid substitution T117A, E118K, E118R or E118A in SEQ ID NO: 1. 2. The mutant chicken interleukin-1β protein of claim 1 , which is a chicken interleukin-1β antagonist. 3. A method of treating a disease caused by avian virus infection, comprising administering to a subject in need thereof an effective amount of a medicament comprising the mutant chicken interieukin-1β protein of claim 1 . 4. The method according to claim 3 , wherein the avian virus infection is avian reovirus, avian influenza virus, Marek's disease virus or Newcastle disease virus infection. 5. The method according to claim 3 , wherein the medicament is administered via an oral route or an intravenous injection. 6. The method according to claim 3 , wherein the mutant chicken interleukin-1β protein inhibits proliferation of avian virus and avian inflammation response.
IL-1 · CPC title
Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title
Antivirals · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.